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Edited by Lukas HuberAbstract Human retinal pigmented epithelial cell (hRPE) pro-
liferation plays a signiﬁcant role in various proliferative diseases
associated to the retina that leads to loss of vision, such as pro-
liferative vitreoretinopathy. In the current study, the role of the
bovine vitreous lipid factor (bVLF) in hRPE cell proliferation
has been investigated. bVLF is a bioactive lipid isolated from
the bovine vitreous body with strong Ca2+-mobilizing activity
in ﬁbroblast. In the ﬁrst approach, the eﬀects of bVLF on
Ca2+-mobilizing activity were investigated in hRPE. The results
showed that bVLF induced, in a dose-dependent manner, a Ca2+
mobilization from PA-sensitive intracellular stores [non-
Ins(1,4,5)P3-sensitive stores], in which extracellular Ca
2+ partic-
ipated. The increase in intracellular Ca2+ was associated with a
dose-dependent inhibiting eﬀect on cell proliferation. At a dose of
10 lg/mL, bVLF caused a 26% or a 44% inhibition in hRPE cell
proliferation during the 3- or the 6-day culture periods, respec-
tively. These eﬀects appear to be speciﬁc in hRPE cells, since
EFGR-T17 ﬁbroblast cells treated with equivalent amounts of
bVLF did not show any inhibiting eﬀects. This inhibitory action
was not associated to apoptotic/necrotic processes. Furthermore,
bVLF inhibited EGF-, bFGF-, IGF-I-, PDGF-, HGF- and
VEGF-induced proliferation of the hRPE cells. Moreover, this
inhibitory response was also observed in FBS-induced hRPE cell
proliferation. bVLF, at a concentration of 10 lg/mL, induced
16% inhibition of proliferation during a culture period of 3 days.
This inhibitory action was greater during the 6-day culture per-
iod, exceeding 40%. With regard to this action, the results
showed that bVLF has a potent inhibitory eﬀect on ERK1/2 acti-
vation, and plays a key role in the control of hRPE cell prolifer-
ation. These observations contribute to the knowledge of
inhibitory factors responsible for keeping antiproliferative envi-
ronment that preserve the RPE-associated activities in normal
states. It advances the interesting possibility that this factor orAbbreviations: AC, adenylate cyclase; [Ca2+]i, intracellular free calcium
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The formation of scar-like ﬁbrocellular membranes on retinal
surfaces is one of the main characteristics of proliferative retinal
diseases [1]. The contraction of these membranes leads to loss of
vision because the retina becomes detached. These membranes
may form as a consequence of retinal ischaemia, as in prolifer-
ative diabetic retinopathy, in which vascularization and a low
content of retinal pigment epithelial cells (RPE) are present
[2]. A second group of membranes, RPE-rich membranes, tends
to be avascular and normally arises following retinal hole for-
mation which allows the access of vitreous to the potential space
between the neuroretina and the RPE cells, as happens in pro-
liferative vitreoretinopathy (PVR) [1,3,4]. In this sense, RPE
cells play a crucial role in both the formation of contractile
membranes in the vitreous cavity and both surfaces of the ret-
ina. In a normal eye, the RPE cells form a conﬂuent monolayer
of highly polarized cells located between the choroids and the
retina, that has numerous functions, including maintaining
the retinal photoreceptor cells adjacent and forming the outer
blood-retinal barrier [5,6]. RPE cells have limited proliferative
capacity, corresponding to the increase in retinal area associ-
ated to growth and age. However, under pathological condi-
tions these cells show the ability to migrate and proliferate in
response to a wide range of autocrine and paracrine cytokines
and growth factors involved in the mediation of cellular chemo-
taxis, cellular proliferation, extracellular matrix production,
wound remodelling and wound contraction [1,7–9].
The vitreous ﬂuid, which is known to contain retina-derived
factors, makes this sample an ideal setting in which to investi-
gate the factors produced by the retina and indirectly explore
the events which are taking place at this level. In this sense,
our interest was centred on identifying atypical bioactive factors
in the vitreous body, i.e., low molecular weight compounds, in
non-pathological conditions. For this purpose, bovine vitreousation of European Biochemical Societies.
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such substances. Among the advantages, it is interesting to note
the amount of starting material available to isolate this type of
factors, an important limitation using human vitreous body.
Thus, the studies developed with bovine vitreous will allow us
to extrapolate the presence of such factors in the human sam-
ples. In this context, recent studies performed in our laboratory
have demonstrated the existence of a bioactive lipid, called bo-
vine vitreous lipid factor (bVLF), isolated from bovine vitreous
body used as the starting material which acts as a potent Ca2+-
mobilizing agent in ﬁbroblasts [10]. The sequential analysis of
its transmembrane signalling pathway has been reported in
EGFR-T17 ﬁbroblasts. bVLF acts through a signalling path-
way diﬀerent from the one described for Ins(1,4,5)P3. Upon li-
gand binding, the receptor activates a signalling pathway
involving a phosphatidylcholine-speciﬁc phospholipase C
(PC-PLC) coupled to a diacylglycerol kinase (DAG-K) inwhich
the intracellular-generated phosphatidic acid (PA) acts on intra-
cellular, non-Ins(1,4,5)P3-sensitive stores, triggering the cal-
cium mobilization [11]. The membrane potential changes
observed in ﬁbroblasts are closely associated with PA-dependent
intracellular calcium mobilization. The rise in calcium evokes a
transient hyperpolarization of the membrane due to the activa-
tion of Ca2+-activated K+ channels, probably of the BK-type.
Moreover, bVLF has no inhibitory eﬀect on gap junctional
intercellular communication [12]. This demonstrates the com-
plexity of the signalling mechanisms that depend on this lipid
factor, still partly characterized, but potentially involved in
the control of various cellular responses. It advances the intrigu-
ing possibility that atypical factors like bVLF may be involved
in the regulation of abnormal proliferative eye processes.
The present study has two aims. The ﬁrst one was to deter-
mine the eﬀects of bVLF on human retinal pigmented epithe-
lial cells (hRPE) cells involved in some pathological eye
diseases. The second one was to observe the proliferative ef-
fects of bVLF on these cells.2. Materials and methods
2.1. Reagents
L-a-Lysophosphatidic acid (oleoyl LPA), forskoline, thapsigargin,
DEAE-Sephadex A25, epidermal growth factor (EGF), basic ﬁbro-
blast growth factor (bFGF), hepatocyte growth factor (HGF), insu-
lin-like growth factor I (IGF-I), platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF) were obtained
from Sigma Chemical Co. Fura-2 pentaacetoxymethylester (fura-2/
AM) was obtained from Molecular Probes. Anti-phosphoERK1/2
and anti-ERK1/2 rabbit polyclonal antibodies were obtained from Cell
Signaling Tec. ECL detection kit, myo-[2-3H]inositol and cAMP deter-
mination kit were obtained from Amersham Pharmacia Biotech. Sep-
pack C18 and HPLC silica columns were obtained from Waters.
2.2. Cell culture
The hRPE cells were isolated as previously described (Capea´ns,
1998) from donor eyes from the Complejo Hospitalario Universitario
de Santiago (Santiago de Compostela, Spain) within 24 h of death fol-
lowing a procedure authorized by the Hospital Committee for Ethics.
Primary culture and early passaged hRPE cells were cultured to 90%
conﬂuence in Dulbeccos modiﬁed Eagles medium (DMEM) supple-
mented with 10% (v/v) foetal calf serum (unless otherwise mentioned)
in a humidiﬁed atmosphere of 95% air, 5% CO2 at 37 C. The media
were supplemented with 100 units/mL penicillin G, 1 mM sodium
pyruvate and 100 lg/mL streptomycin sulphate. The purity of the cells
was evaluated by immunocytochemical staining for cytokeratin (AE1/
AE3) as previously described [13]. The cells from passages 2 to 6 were
used in the present study.The EGFR-T17 cell line, a clone of mouse NIH-3T3 ﬁbroblasts
overexpressing EGF receptors, was cultured to 80% conﬂuence for 2
days in Dulbeccos modiﬁed Eagles medium (DMEM) supplemented
with 10% (v/v) foetal calf serum. The media were supplemented with
penicillin G (100 units/mL) and streptomycin sulphate (100 lg/mL).
The cells were grown in a humidiﬁed atmosphere of 95% air, 5%
CO2 at 37 C and were shifted to DMEM containing 0.5% foetal calf
serum 24 h prior to experimentation.2.3. Puriﬁcation procedure
The bVLF puriﬁcation procedure has been described in detail else-
where [10,11]. Brieﬂy, lipids were extracted from a bovine vitreous
homogenate with chloroform:methanol and bVLF was puriﬁed from
a crude lipid extract by solid phase extraction (Set-pack C18), silica col-
umn chromatography, anion exchange chromatography (DEAE-
Sephadex A25, acetate form), solid phase extraction (Set-pack C18)
and HPLC (silica column). The entire puriﬁcation procedure was fol-
lowed by thin layer chromatography and a intracellular free calcium
concentration ([Ca2+]i) mobilization test on EGFR-T17 cells.2.4. Calcium measurements
The intracellular [Ca2+]i measurements were performed in cell sus-
pensions using the ﬂuorescent Ca2+ indicator fura-2 as previously
described for EGFR-T17 cells [11,14]. Brieﬂy, the hRPE and EGFR-
T17 cells were resuspended (2 · 100-mm plates/mL) in Krebs–Ringer–
Hepes (KRH; 125 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 2 mM CaCl2, 6 mM glucose, and 25 mM HEPES/NaOH,
pH 7.4) and loaded with 3–5 lM fura-2/AM. For each measurement,
approximately 2 · 106 cells were used in 2 ml of KRH. Ca2+ readings
were performed in ratio mode, using kex1 = 345, kex2 = 380 and
kem = 490 nm, and calibrated using the cell lysis method [15].2.5. Inositol phosphate measurements
The hRPE cells were labelled in 6-well multiwells by incubation in a
1:4 mixture of Dulbeccos modiﬁed Eagles medium and inositol-free
basal medium of Eagle, containing 10% dialysed foetal bovine serum
(FBS) (ﬁnal inositol concentration, 10 lM), supplemented with myo-
[2-3H]inositol (2 lCi/mL) for 48 h. The incubation medium was re-
moved, and the monolayers were washed three times with cold KRH
and then incubated for 10 min at 37 C in KRH supplemented with
10 mM LiCl. The cells were stimulated with test agents for 30 min,
after which the reactions were stopped by the addition of 2 ml ice-cold
10% (v/v) trichloroacetic acid. Acid-soluble radioactivity was trans-
ferred to glass tubes and washed ﬁve times with diethyl ether, and
the total [3H]-inositol phosphates (InPs) were analysed [16].2.6. Measurement of intracellular cAMP levels
The conﬂuent hRPE monolayer cells (about 70–80%) were resus-
pended in serum-free DMEM (1 · 100 mm plate/1.5 ml; 5–6 · 105 cells
per aliquot), and then incubated for 30 min at 37 C with 1.0 mM 3-
isobutyl-1-methylxanthine (IBMX) to prevent enzymatic degradation
of cAMP. Test agents in fresh IBMX-medium were added to the cells,
and the incubation was continued for another 30 min at 37 C. Subse-
quently, the medium was then removed, and the cells were lysed with a
buﬀer solution containing 4 mM EDTA. Fifty microliters of lysate was
used to assay cAMP determination by means of a competitive protein-
binding assay using a commercial kit (Amersham Pharmacia Biotech)
with [8-3H]cAMP as the tracer. The assays were performed in tripli-
cate.2.7. Proliferation assays
The hRPE cells (passages 3–6) were seeded in 24-well plates at a den-
sity of 30 · 103 cells per well in 500 lL DMEM/10% FBS. After 3 days,
the medium was changed and the cells were cultured in a serum-free
medium for 24 h. The cells were then treated with the diﬀerent agents
in fresh DMEM. After incubation at time indicated in each speciﬁc
experiment, the cells were washed and the remaining adherent cells
were trypsinized and counted using a Coulter Counter. The EGFR-
T17 cells were plated into 24-well culture plates at a density of
15 · 103 cells per well in 500 lL DMEM/10% FBS. The medium was
changed to DMEM supplemented with 0.5% FBS and the cells were
incubated for 24 h. The cells were then treated with the diﬀerent agents
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0.5% FBS. After 48 h, the cells were washed, trypsinized and counted.
In all cases, triplicate dishes were used for each experiment point.
2.8. Apoptosis assays
Apoptosis and necrosis were determined by staining with annexin V-
FITC and ﬂow cytometry. The hRPE cells (passages 3–6) were seeded
in 6-well plates in DMEM/10% FBS. After 3 days, the medium was
changed and the monolayers were cultured in a serum-free medium
for 24 h. The cells were treated with bVLF at the times indicated
and then harvested by brief trypsinization. Samples were pelleted by
centrifugation, washed with an incubation buﬀer (10 mM HEPES/
NaOH, pH 7.4, 140 mM NaCl, and 5 mM CaCl2), centrifuged, and
suspended in 400 lL of this buﬀer. The cells were then incubated for
15 min with annexin V-LFLUOS and propidium iodide, accordingFig. 1. bVLF induced calcium signal in hRPE cells. The hRPE cells were st
were measured with the ﬂuorescent probe fura-2. (A) bVLF-induced calc
endoplasmic reticulum calcium pumps inhibitor thapsigargin (50 nM, 30 mi
ﬁnal). (D) Dose response of bVLF-induced calcium mobilization. The resu
expressed as the percentage of maximum response. (E) Accumulation of cAM
(1 lM). Results (means ± S.E., n = 9) are expressed as the percentage over co
mL) and FCS (10%, v/v) on PtdIns(4,5)P2 hydrolysis. Data (means ± S.E., nto the manufacturers instructions. The percentages of annexin V-posi-
tive cells and propidium iodide-negative cells were determined by ﬂow
cytometric analysis (Beckton–Dickinson, FACScan).
2.9. Western blot analysis
The hRPE cells (passages 3–6) grown to conﬂuence in 6-well plates
were serum-starved for 24 h in DMEM and then stimulated with the
appropriate agents at diﬀerent times. At the desired times, the media
were aspirated, and the cells were incubated for 10 min with the lysis
buﬀer (50 mM Tris/HCl, pH 7.4, 150 mM NaCL, 1 mM EDTA, 1%
NP-40, 0.25% Na-deoxycholate, 1 mM PMSF, 1 lg/mL aprotinin,
1 lg/mL leupeptin, 1 lg/mL pepstatin, 1 mM Na3VO4, and 1 mM
NaF) at 4 C. The solubilized RPE cell lysates were pre-cleared by cen-
trifuging at 14000 · g for 10 min. The samples were separated with
SDS–PAGE (15% polyacrylamide gels), transferred onto nitrocelluloseimulated with puriﬁed bVLF, and changes in the intracellular calcium
ium mobilization (5 lg/mL) in control cells. (B) Eﬀect of the sarco/
n). (C) Inhibition of bVLF calcium mobilization by Ni2+ ions (5 mM
lts (means ± S.E. of three independent experiments in triplicate) are
P in response to bVLF (12.5 lg/mL), LPA (5.0 lg/mL) and forskoline
ntrol (untreated cells). (F) Eﬀect of bVLF (12.5 lg/mL), LPA (5.0 lg/
= 9) are expressed as the percentage of the control values. (\, P < 0.05).
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ERK1/2 (Thr202/Try204) and polyclonal antibodies directed against
the ERK1/2. The primary antibodies were detected with horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody. The
ECL substrate was used to reveal bands, according to the manufac-
turers instructions.
2.10. Data analysis
The results were expressed as the mean ± S.E. Diﬀerences between
means were evaluated by one-way analysis of variance (ANOVA).
The Fishers protected least signiﬁcant diﬀerence (PLSD) method
was used to determine speciﬁc diﬀerences between means when deter-
mined as signiﬁcant by ANOVA main eﬀects analysis (\, P < 0.05).3. Results
3.1. Inositol 1,4,5-triphosphate-independent Ca2+ mobilization
induced by bVLF in hRPE cells
In the ﬁrst approach, the eﬀects of bVLF on hRPE cells were
evaluated by means of intracellular calcium mobilization.
When bVLF was administered to hRPE cells, a prominent
[Ca2+]i peak was observed that was followed by a sustained
plateau with no return to prestimulatory levels (Fig. 1A).
The initial Ca2+ peak was due to redistribution from intracel-
lular stores, as shown by the absence of a peak observed in the
cells pre-treated for 30 min with 50 nM thapsigargin, a sarco/
endoplasmic reticulum calcium pump blocker that empties
the intracellular calcium stores (Fig. 1B). The sustained pla-
teau that follows the Ca2+ peak is the result of an inﬂux of
Ca2+ from the extracellular medium, because it was absent in
the presence of extracellular Ni2+ (Fig. 1C). The bVLF-in-
duced Ca2+ rise was dose-dependent (Fig. 1D), with a half-
maximal response at approximately 1.5 lg/mL with saturation
at doses in excess of 5 lg/mL. To gain further insight into the
mechanism of action of bVLF on hRPE cells, the accumula-
tion of cAMP and the generation of inositol phosphate were
evaluated. As Fig. 1E shows, there was a signiﬁcant inhibition
in cAMP levels after bVLF treatment (12.5 lg/mL). cAMP lev-Fig. 2. Eﬀects of pertussis toxin (PTX), PC-PLC (D609) and DAG-K (R590
cells stimulated with a saturating dose of bVLF (5 lg/mL). (B) bVLF-induce
PC-PLC inhibitor D609 (10 lM, 5 min) on the bVLF-induced calcium mobili
30 min) before the administration of bVLF. The experiments were performeels were unaltered by LPA (5 lg/mL), while they were elevated
in response to forskoline (1 lM). On the other hand, bVLF
(12.5 lg/mL) signiﬁcantly reduces InPs formation, whereas
LPA (5 lg/mL) and FBS (10% v/v) induced a signiﬁcant rise
in InsP (Fig. 1F). These results rule out the possibility that
bVLF induces calcium mobilization via the activation of phos-
phatidylinositol-speciﬁc phospholipase C (PI-PLC) or via AC/
cAMP/protein kinase A (PKA). Furthermore, preincubation
of the cells with PTX (100 ng/mL, 2 h) resulted in a clearly
reduced bVLF-induced Ca2+ rise (Fig. 2B), suggesting the
involvement of a PTX-sensitive G protein not coupled to PI-
PLC, probably belonging to a Gi/G0 subfamily. The involve-
ment of Gi activation is supported by the inhibition of cAMP
accumulation. Previous works had already shown that addi-
tion of bVLF induces an increase of [Ca2+]i in EGFR-T17 cells
as a consequence of the release of Ca2+ from Ins(1,4,5)P3-
insensitive intracellular stores with no participation of extra-
cellular Ca2+ [11]. In these cells, [Ca2+]i mobilization is
activated by PC-PLC coupled to DAG-K where PA is respon-
sible for the Ca2+ signal. In order to check whether bVLF
could be using the signalling pathway activated in EGFR-
T17 cells, the DAG-K inhibitor R59022 and the PC-PLC
inhibitor D609 were used. As the inhibition of DAG-K causes
accumulation of DAG, the experiments was performed in the
presence of the protein kinase C (PKC) inhibitor staurosporine
(1 lM). As Fig. 2C shows, the preincubation with the PC-PLC
inhibitor D609 (10 lM, 5 min) caused a clear-cut blockade of
the bVLF-induced calcium rise. In addition, the blockade of
calcium transient after preincubation with the DAG-K inhibi-
tor (10 lM, 30 min; Fig. 2D) suggested that this pathway was
taking part in the triggering of calcium redistribution.
3.2. The inhibitory eﬀect of bVLF on hRPE cell proliferation
The eﬀects of diﬀerent doses of bVLF on hRPE cells cul-
tured in DMEM is presented in Fig. 3. Under these conditions,
the hRPE cells showed a basal proliferation due basically to
their own autocrine mitogenic activity [17–21]. After 3 days22) inhibitors on the bVLF-induced calcium mobilization. (A) Control
d calcium signal in the presence of PTX (100 ng/mL, 2 h). (C) Eﬀect of
zation. (D) Cells pretreated with the DAG-K inhibitor R59022 (10 lM,
d in the presence of the PKC inhibitor staurosporine (1 lM).
Fig. 3. Inhibition of basal hRPE cell proliferation by bVLF measured
by cell counting. The cells were treated with diﬀerent doses of bVLF
and equal volumes of the vehicle (MeOH). After the incubation time, 3
(A) or 6 (B) days, the cells were trypsinized and counted using a
Coulter Counter. Co: hRPE cells originally seeded for the assays.
Control: untreated cells after incubation period. Data are expressed
as means ± S.E. of three independent experiments in triplicate
(\, P < 0.05).
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treated cells (control) with a dose of 5.0 lg/mL and 74 ± 7% at
doses of 10.0 lg/mL. After 6 days, there was 56 ± 3% the num-
ber of control cells at a dose of 10.0 lg/mL. This eﬀect appears
to be speciﬁc for bVLF, since cells treated with equivalent
amounts of MeOH (vehicle) did not appear to be signiﬁcantly
aﬀected in comparison with control cells. As the inhibition ob-
served after the application of the bVLF could be a result of
apoptosis or necrosis, annexin V binding was measured. The
cells were treated with bVLF (10.0 lg/mL) for 3 and 6 days
in DMEM, and were stained with annexin V and propidium
iodide (PI). After 3 days, it was clear that bVLF did not alter
the number of cells undergoing spontaneous apoptosis, 6.9%
versus 7.4% respectively (Fig. 4A and C). After 6 days, a total
of 8.5% of the cells underwent apoptosis after bVLF treat-
ment, compared to 6% of the untreated cells (Fig. 4B andC). Furthermore, treatment with bVLF (10.0 lg/mL) did not
cause an increase in the number of cells undergoing necrosis
compared to the untreated cells (Fig. 4D).3.3. The inhibitory eﬀects of bVLF on various mitogens in hRPE
cells
The dose–response curve obtained for bVLF (Fig. 3) in cell
proliferation clearly suggests an inhibitory role for this factor
in growth factor-activated hRPE cell proliferation. To test this
hypothesis, the cells were treated with a dose of EGF (100 nM)
in combination with diﬀerent doses of bVLF. As Fig. 5A
shows, treatment of the cells with bVLF for a period of 3 days
resulted in a dose-dependent inhibition reaching 25% at a dose
of 10 lg/mL (P < 0.05). Furthermore, bVLF inhibited bFGF-
induced cell proliferation (1 nM; Fig. 5B), with a dose-dependent
inhibition reaching 33% at a dose of 10 lg/mL for bVLF dur-
ing a 3-day culture period (P < 0.05). To evaluate the eﬀects of
bVLF on other growth factors, the hRPE cells were treated
with saturating doses of IGF-I (25 ng/mL), PDGF (20 ng/
mL), HGF (50 ng/mL), or VEGF (40 ng/mL) alone and in
combination with bVLF. After a culture period of 3 days,
bVLF, at a dose of 10 lg/mL, also inhibited the IGF-I-,
PDGF-, HGF- or VEGF-induced proliferation of RPE cells
by 25%, 30%, 17% and 41%, respectively (P < 0.05; Fig. 6A).
The complex interaction among mitogenic factors represents
an important mechanism that regulates the magnitude of the
cellular responses either in normal or pathological conditions.
The eﬀects of bVLF were evaluated working with the potent
mitogen FBS at a concentration of 10% (v/v). As Fig. 6B
shows, treatment of the cells with bVLF (10 lg/mL) inhibited
FBS-induced proliferation of hRPE cells by 16% after 3 days
and by more than 40% on day 6 (P < 0.05).3.4. bVLF controls mitogenic responses via the inhibition of
ERK1/2 activity
The phosphorylation of the MAPK signalling pathway
ERK1/2 after FBS stimulation, alone or in combination with
bVLF, was examined in hRPE cells. In control cells, ERK1/
2 phosphorylation was clearly detected at 10 min after FBS
treatment (10%, v/v) with a subsequent slow reduction (Fig.
6C). At a dose of 10 lg/mL, bVLF attenuated FBS-activated
ERK1/2 phosphorylation (Fig. 6C), this inhibitory action ap-
pears to reach a maximum for 10 min after stimulation with
a slow decrease within 60 min. Immunoblots with the anti-
ERK1/2 antibody demonstrated that the lysates applied con-
tained equivalent amounts of the ERK protein (Fig. 6C).3.5. Eﬀects of bVLF on EGFR-T17 cell proliferation
When bVLF (5 lg/mL) was administered to EGFR-T17
cells, a prominent, transient [Ca2+]i peak was observed that
was followed by a return to the prestimulatory levels (Fig.
7A). This rise in calcium is due to an intracellular calciummobi-
lization from PA-sensitive intracellular stores with no partici-
pation of the extracellular calcium, as previously described
[11]. However, this mobilization of calcium was not followed
by an inhibitory eﬀect on EGFR-T17 cell proliferation (Fig.
7B). To test the regulatory role of this factor on growth fac-
tor-activated EGFR-T17 cell proliferation, the cells were trea-
ted with a proliferative dose of EGF (100 nM) in combination
with diﬀerent doses of bVLF. As Fig. 7C shows, treatment of
Fig. 4. Eﬀects of treatment with bVLF on apoptosis induction in hRPE cells. The rate of apoptosis was evaluated using FACS analysis of
ﬂuorescent-conjugated annexin V and PI. The response to annexin V is plotted on the x-axis and the response to PI is plotted on the y-axis. Cells
negative for both PI and annexin V staining are live cells (bottom left); PI-negative, annexin V-positive staining cells are early apoptotic cells (bottom
right); PI-positive annexin V-positive staining cells are primarily cells in the late stages of apoptosis (top right); PI-positive, annexin V-negative
staining cells are necrotic cells (top left). bVLF-treated cells (10.0 lg/mL) showed 4.5% annexin V staining at 3 days after treatment (A, right panel);
4.9% of cells were annexin V-positive in the control group 3 days after serum starvation (A, left panel). After 6 days, bVLF-treated cells (10 lg/mL)
showed less than 5% were annexin V-positive (B, right panel). In the control group, 3.8% of cells showed 4.5% annexin V staining (B, left panel). (C)
and (D) The time courses of the eﬀect of bVLF (10.0 lg/mL) on apoptosis (Annexin V-FITC positive, propidium iodide-negative) and necrosis,
respectively. EtOH-treated cells were used as positive control (6 days). Data (means ± S.E. of three independent experiments in triplicate) are
expressed as the percentage of apoptotic (Annexin V-FITC positive, propidium iodide-negative) and necrotic (propidium iodide-positive) hRPE cells.
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this growth factor in a signiﬁcant way. Furthermore, similar re-
sults were obtained for the diﬀerent doses of bVLF tested on
bFGF-induced cell proliferation (1 nM, Fig. 7D).4. Discussion
This study has unambiguously shown that bVLF, a bioac-
tive lipid factor isolated from bovine vitreous body is aninhibitor of hRPE cell proliferation and could be considered
a novel growth-inhibitory factor that does not operate
through apoptotic/necrotic processes. bVLF is a complex li-
pid that acts as a potent Ca2+-mobilizing agent in the
EGFR-T17 ﬁbroblast [11]. The present study demonstrates
that the intracellular mobilization of calcium is also an early
signal triggered by bVLF in the hRPE cells, a cell line that
play an important role in some proliferative diseases associ-
ated to the retina, such as proliferative vitreoretinopathy.
This suggests that the hRPE cells express receptors for this
Fig. 5. The inhibitory eﬀects of bVLF on the EGF- and FGF-induced
proliferation of hRPE cells. The hRPE cells were treated with EGF
(100 nM; A) or FGF (1 nM; B) alone and in combination with
diﬀerent doses of bVLF. The inhibitory eﬀect of bVLF was scored
after 3 days of culture period. Data, expressed as the percentage of the
maximum proliferation, are the means ± S.E. of the results obtained
from three independent experiments in triplicate (\, P < 0.05).
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cellular signalling transduction mechanisms. The bVLF-acti-
vated calcium signal is generated by the redistribution of
calcium from intracellular stores with signiﬁcant participation
of extracellular calcium, acting through the same signalling
pathway as the one used by this factor in the EGFR-T17
ﬁbroblast. Upon ligand binding, the receptor activates a
PC-PLC through a PTX-sensitive G protein, that results in
the generation of phosphocholine and DAG. The latter is
converted to PA by means of a DAG-K, with no activation
of PKC, then PA acts on non-Ins(1,4,5)P3-sensitive stores,
triggering the calcium movement. In these cells, the intracel-
lular calcium pool is functionally coupled to calcium-dependent
calcium entry. It is interesting to note that the magnitude of
the calcium inﬂux was small in bVLF-treated EGFR-T17ﬁbroblasts, cells that express store-operated calcium channels
[11]. This fact suggests that the calcium pool mobilized by
bVLF in the hRPE cells is functionally coupled to the cal-
cium inﬂux through a calcium channel unexpressed in
EGFR-T17 cells. The molecular mechanisms by which bVLF
activates the calcium inﬂux remains to be precisely deﬁned.
In the present study a new functional property is added to
bVLF, in which this lipidic factor has a powerful dose-depen-
dent antiproliferative eﬀect on hRPE cells. Because viability
in hRPE cell cultures treated with bVLF at eﬀective antiprolif-
erative doses was equivalent to the control cells, the antiprolif-
erative action of bVLF supports its possible role as agent for
the prevention of proliferative vitreoretinopathy. Although this
factor is isolated from bovine vitreous body, its inhibitory eﬀect
suggests the intriguing possibility that this factor, or a factor
with characteristics common to bVLF, may be physiologically
involved in the regulation of RPE cell proliferation in combina-
tion with other endogenous inhibitors, such as substance P, cal-
citonin gene related peptide, vasointestinal polypeptide and
neuropeptide Y [22]. Thus, the regulatory interaction between
proliferation stimulators and inhibitors keeps the cell popula-
tion in the retina under control in normal healthy conditions.
In fact, bVLF caused a signiﬁcant blockade of the mitogenic ef-
fect of diﬀerent isolated growth factors such as EGF, bFGF,
IGF-I, PDGF, HGF and VEGF on the hRPE cells in culture.
In this sense, it is important to denote that the discrete prolifer-
ative response obtained after stimulation of hRPE cells with
diﬀerent mitogens was due to the basal proliferative activity,
an inherent property of the cells, that is determined by several
autocrine loops [17–21]. Consequently, the eﬀect of bVLF was
tested on hRPE cell proliferation induced by a combination of
diﬀerent factors, such as are present in FBS. Despite basal pro-
liferation, hRPE cells showed proliferative capacity under our
experimental conditions. After 6 days, FBS-stimulated cells
showed an increase of 126% respect to control cells
(120087 ± 8434 cells versus 53383 ± 3761 cells) and 249% re-
spect to hRPE cells originally seeded (35000 ± 100 cells). Un-
der these conditions, the treatment of the cells with bVLF
caused a signiﬁcant inhibitory eﬀect on FBS-mediated cell pro-
liferation after 3 days of treatment, which was greater after 6
days of treatment. Regarding the mechanism of action, bVLF
appeared to inhibit FBS-induced ERK1/2 phosphorylation.
This result is consistent with previous ﬁndings indicating that
the ERK1/2 pathway is the main pathway that control FBS-in-
duced RPE cell proliferation [23–25]. It was demonstrated that
the Ras/Raf/MEK/ERK signalling pathway is activated in
FBS-induced RPE cell proliferation. This pathway appears to
be regulated by a PKA-independent cAMP-signalling pathway,
which is mainly controlled by small G protein Rap1 [23]. As
bVLF induces a signiﬁcant inhibition of cAMP production,
the signalling pathway involved in the modulation of MAP ki-
nase cascade appears to be independent of Rap1, however
molecular mechanisms by which bVLF blocks ERK1/2 phos-
phorylation are still to be precisely deﬁned. The kinetics of
ERK activation are critical for determining the consequence
of ERK signalling, and reductions in ERK activation may be
physiologically signiﬁcant [26–28]. The FBS-stimulated hRPE
cells showed changes in the level of ERK1/2 phosphorylation
at least 60 min after treatment with FBS. The activation of
the bVLF-associated signalling pathway blocks ERK phos-
phorylation for an extended period of time, during at least
30–60 min, suggesting that the extent of this inhibition may
Fig. 6. The inhibitory eﬀect of bVLF on the mitogenic eﬀects of various growth factors on hRPE cells. (A) The hRPE cells were treated with IGF-I
(25 ng/mL), PDGF (20 ng/mL), HGF (50 ng/mL), or VEGF (40 ng/mL) alone and in combination with a saturating dose of bVLF (10 lg/mL). The
inhibitory eﬀect of bVLF was scored after 3 days of the culture period. (B) The proliferation of hRPE cells treated with 10% FBS alone or in
combination with bVLF (10 lg/mL) was studied after 3 and 6 days of the culture period. Data (means ± S.E. from three independent triplicate
experiments) are expressed as the percentage of the maximum proliferation (\, P < 0.05). (C) The cells were treated with 10% FBS (upper) or 10%
FBS in combination with bVLF (10 lg/mL; lower) for the times indicated, and total lysates were separated by SDS–PAGE. Western blotting was
carried out using anti-phosphorylated ERK1/2 (upper) or an anti-ERK1/2 (lower) antibodies.
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on ﬁbroblasts might support this hypothesis.
In a normal state, the RPE-associated activities are preserved
by a balanced proliferative–antiproliferative surroundings as
well as by a balance between adhesive and counter-adhesive
molecules that maintain RPE cells adhered to Bruchs mem-
brane [1]. In the development of proliferative vitreoretinopa-
thy, RPE cells migrate from their physiological location to
the preretinal and subretinal spaces where they dediﬀerentiate
to myoﬁbroblasts and then begin to proliferate. Several growth
factors and cytokines appear to be responsible for the evolu-
tion of such a disease. This fact is based on the ﬁndings that
factors such as PDGF [29–31], TNF-a [32,33], HGF [20], IL-
1, IL-6 [34–37], IL-8, MCP-1, MCSF [38,39], EGF [40,41],
TGF-b1 [42] or FGF [43,44] are increased in the vitreous body,
sub-retinal ﬂuid as well as in the epiretinal membranes of pa-tients with PVR [4]. PVR might thus be interpreted as a result
of a cascade of interactions among cytokines and growth
factors with the intraocular cell populations, mainly RPE cells,
and non-habitual cells, such as macrophages and lymphocytes,
that enter in the vitreous cavity when the ocular barriers break
down [45]. However, it seems clear that growth factors and
cytokines function late in the temporal sequence of the devel-
opment of PVR. Therefore, this might reinforce the idea that
the initial processes of the development of PVR are related
to an imbalance between adhesive and counter-adhesive mole-
cules stimulating the RPE cells to dissociate from Bruchs
membrane together with a change in the dynamic balance be-
tween proliferative and antiproliferative factors.
In conclusion, our results demonstrate that bVLF has an
antiproliferative eﬀect on hRPE cells. This factor inhibited
EGF-, bFGF-, IGF-I-, PDGF-, VEGF and FBS-induced
Fig. 7. Eﬀect of bVLF on the proliferation of EGFR-T17 cells. (A) bVLF-induced (1 lg/mL) calcium mobilization in EGFR-T17 cells. (B) Dose
response of the eﬀect of the bVLF on the EGFR-T17 cell proliferation. The cells were then treated with diﬀerent doses of bVLF or equal volumes of
the vehicle (MeOH). Data (means ± S.E. of three independent experiments in triplicate) are expressed as the percentage of the control values. (C) and
(D) EGFR-T17 cells were treated with EGF (100 nM) or FGF (1 nM) alone and in combination with diﬀerent doses of bVLF. Data, expressed as the
percentage of the maximum proliferation, are the means ± S.E. of results obtained from three independent experiments in triplicate.
4028 E. Dı´az-Rodrı´guez et al. / FEBS Letters 579 (2005) 4020–4030proliferation of hRPE cells through the inhibition of the
ERK1/2 signalling pathway. This adds a new function to those
already attributed to this extracellular lipid factor, still partly
characterized, but potentially involved in the control of prolif-
erative eye processes.
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